Clinical Trials Logo

Refractory Chronic Cough clinical trials

View clinical trials related to Refractory Chronic Cough.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05962151 Recruiting - Clinical trials for Refractory Chronic Cough

Refractory Chronic Cough Improvement Via NAL ER (RIVER)

RIVER
Start date: November 30, 2023
Phase: Phase 2
Study type: Interventional

A 2-period crossover study for the treatment of cough in patients with Refractory Chronic Cough via Nalbuphine ER (NAL ER). Each period will last 21 days and are separated by 21 days. Subjects will be randomized in Treatment Period 1 to either NAL ER or matching placebo and evaluated for 21 days. After completion of the first phase, subjects who received NAL ER will crossover to placebo and subjects who received placebo will crossover to NAL ER to complete Treatment Period 2.

NCT ID: NCT05600777 Recruiting - Clinical trials for Refractory Chronic Cough

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

Start date: January 13, 2023
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

NCT ID: NCT05599191 Recruiting - Clinical trials for Refractory Chronic Cough

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

CALM-1
Start date: October 25, 2022
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

NCT ID: NCT05110144 Recruiting - Clinical trials for Refractory Chronic Cough

Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough

MACS-1
Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with refractory chronic cough (RCC)

NCT ID: NCT03662269 Recruiting - Clinical trials for Refractory Chronic Cough

Indomethacin for Refractory Chronic Cough

Start date: October 22, 2018
Phase: Phase 3
Study type: Interventional

Chronic cough is a common complain of patients in respiratory clinic and its global prevalence was up to 9.6%. Persistent cough of unexplained origin is a significant health issue that occurs in up to 5% to 10% of patients seeking medical assistance for a chronic cough and from 0% to 46% of patients referred to specialty cough clinics. Previous studies showed that sputum prostaglandin D2( PGD2) and prostaglandin E2 (PGE2) concentrations were significantly higher in chronic cough. And some research showed that Inhaled PGE2 /PGF2α /PGD2 / PGI2/ 6-oxo-PGF1a could induced cough. And PGE2 /PGF2α/PGI2/thromboxane A2 (TXA2) also increased the sensitivity of the cough reflex. All these five primary prostaglandins were synthesized though the metabolism of arachidonic acid via the cyclooxygenase pathway. Indomethacin is a strong inhibitor of cyclooxygenase , which decrease the level of prostaglandins in airway. The investigator's preliminary study showed that indomethacin could relieve cough and improve cough sensitivity of some patients with refractory cough. Therefore this randomized, double-blind, placebo-controlled trial were designed to investigate whether indomethacin can relive cough in patients with refractory cough and to explore the possible mechanism of indomethacin in improving cough in patients with refractory cough.